Filing Flows › LifeStance Health Group (LFST) › Q3 2026 › vs Q2 2026
LifeStance Health Group (LFST) Q3 2026 vs Q2 2026 (quarter over quarter)
LifeStance Health Group's revenue rose $20.5M (+5%) from $435M in Q2 2026 to $456M in Q3 2026. Operating margin 7.3% against 7.0% (+0.2 pts).
LifeStance Health Group, Q3 2026: revenue $456M (+25% year over year), operating margin 7.3%, net earnings $22.4M, operating cash flow $37.0M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 7.3% | 7.0% | +0.2 pts |
| Net margin | 4.9% | 5.4% | -0.5 pts |
| Free cash flow margin | 4.9% | 20.2% | -15.3 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $456M | $435M | $20.5M | +5% |
| Operating profit | $33.1M | $30.7M | $2.4M | +8% |
| Costs & expenses | $423M | $405M | $18.1M | +4% |
| Pre-tax earnings | $27.4M | $27.5M | −$54K | -0.2% |
| Other expense, net | $5.7M | $3.2M | $2.5M | +78% |
| SG&A | $113M | $108M | $5.2M | +5% |
| Other operating costs | $309M | $297M | $12.8M | +4% |
| Net earnings | $22.4M | $23.6M | −$1.2M | -5% |
| Income tax | $5.0M | $3.8M | $1.2M | +31% |
| Depreciation & amortization | $12.1M | $11.3M | $743K | +7% |
| Share-based compensation | $18.2M | $19.7M | −$1.6M | -8% |
| Working capital & other | $15.6M | −$45.2M | $60.8M | — |
| Operating cash flow | $37.0M | $99.9M | −$62.9M | -63% |
| Free cash flow (OCF − capex) | $22.4M | $87.9M | −$65.6M | -75% |
| Capital expenditures | $14.7M | $12.0M | $2.7M | +22% |
Questions
How much did LifeStance Health Group's revenue grow quarter over quarter in Q3 2026?
LifeStance Health Group's revenue rose $20.5M (+5%) from $435M in Q2 2026 to $456M in Q3 2026. Operating margin 7.3% against 7.0% (+0.2 pts).